YOKNEAM, ISRAEL--(Marketwire - March 29, 2012) - Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that it will host a joint symposium on Body Shaping featuring its VelaShape body contouring system and the recently acquired UltraShape focused ultrasound fat lipolysis system at the 2012 Anti-Aging Medicine World Congress & Medispa Conference in Monte Carlo. The symposium will feature an overview of Syneron's complementary product offerings for body shaping and a review of the pre-clinical and clinical experience with the UltraShape system. It will also feature two thought-leading physician speakers that will discuss their experience with the VelaShape and UltraShape systems.
Brunch Symposium - "NEW Opportunities & Trends in the Dynamic Body Shaping Arena"
Shimon Eckhouse, Ph.D., Co-founder and Chairman of the Board of Directors of Syneron Medical
Lior Greenbaum, Ph.D., Clinical Director of UltraShape
Chris Inglefield, M.D., Plastic Surgery Clinic at the London Bridge Hospital
Dean Adel, M.D., Head of Plastic Surgery Division at Rabin - Schneider Medical Center, Petah Tikva
Click here for speaker biographies and event agenda.
Le Meridien Beach Plaza Hotel
22 Avenue Princesse Grace
Monte Carlo 98000
Louis P. Scafuri, Chief Executive Officer of Syneron Medical, said, "The symposium provides the first opportunity following the acquisition of UltraShape for Syneron to highlight the synergies associated with our proprietary technologies and the UltraShape focused ultrasound technology to deliver comprehensive body shaping treatments. More than 7,000 VelaShape systems have been sold worldwide since its launch, demonstrating the strong patient demand for body contouring treatments with our safe and efficacious elōs technology. We believe there is a tremendous opportunity to offer our VelaShape customers the UltraShape system to further enhance their patients' body shaping results. Syneron remains committed to be the global market leader in non-invasive body contouring."
Shimon Eckhouse commented, "The UltraShape acquisition expanded Syneron's leadership position in the body shaping market, where we already achieved strong results with our VelaShape family of products. Looking forward, we believe there is a great clinical opportunity for physicians to utilize these systems both individually or in combination to achieve synergistic results."
Syneron also announced the European launch of the GentleMax Pro® system and the global launch of the eStyle Motif system at the 2012 Anti-Aging Medicine World Congress & Medispa Conference.
GentleMax Pro®: building upon the Gold Standard technology of the Gentle Family™ of lasers, the new GentleMax Pro offers more power and versatility than any other multi-wavelength hair reduction device. GentleMax Pro features the industry's largest spot size of 18mm coupled with tremendous fluence options and pulse width range making it a must have device for any thriving laser hair removal practice.
eStyle Motif™: multi-application platform that can perform skin tightening, skin rejuvenation, hair removal and acne treatment procedures with one compact system. The Motif applicator, which was first introduced with the Company's eLase laser hair removal system, allows for virtually pain-free hair removal with far shorter treatment times than competitive devices.
Mr. Scafuri added, "In its initial U.S. launch, the GentleMax Pro was well received by both physicians and patients that have come to trust the Candela and Gentle brands. We expect to receive similar strong adoption in Europe as practitioners upgrade to newest and most advanced hair removal system available today. With the eStyle Motif, we are providing our customers with four of the most in-demand aesthetic applications in a single, modular system that allows a practice to add applications as their business grows. It also features our pain-free hair removal innovation, the Motif applicator, which brings additional differentiation and value to our customers and their patients."
The GentleMax Pro and eStyle Motif products, along with the recently launched eTwo™, CO2RE™, eLase with Motif, and elure Advanced Skin Lightening™ systems, will be featured at the Company's booth at the conference.
About Syneron Medical Ltd.
Syneron Medical Ltd. -- a company devoted to real technology, real science and real results -- is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company's aspiration and commitment to innovation expands Syneron's offering beyond medical device into the largest in-demand applications in beauty -- skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.